Donor immune cells for advanced solid tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This early-phase trial tests a new type of cell therapy using donor immune cells (called CAR-γδT cells) that are engineered to attack a protein called B7H3 found on many solid tumors. The goal is to see if this treatment is safe and could help people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer that has not responded to standard treatments.
- Your tumor has a specific protein called B7H3 (confirmed by a biopsy test).
- You are in reasonably good health, able to care for yourself, and have a life expectancy of at least 3 months.
- Your blood counts, liver, kidney, and heart function are within required limits.
- If you are in the surgical group, your cancer is limited to the lining of the belly or ovarian cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-DC, which uses your immune cells to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
Hear when a new Peritoneal (Metastatic) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.